---
title: "Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271253280.md"
description: "Oramed Pharmaceuticals Inc. announced that board member Leonard Sank will resign from the board effective January 1, 2026, after 18 years of service. His departure is not due to any disagreements, indicating a smooth governance transition. This change may impact the board's composition and institutional knowledge. The current analyst rating for ORMP stock is a Hold with a $3.00 price target, reflecting a neutral outlook due to a strong balance sheet but concerns over weak operations and cash burn."
datetime: "2025-12-31T22:00:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271253280.md)
  - [en](https://longbridge.com/en/news/271253280.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271253280.md)
---

# Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Oramed Pharm ( (ORMP) ) just unveiled an update.

On December 31, 2025, Oramed Pharmaceuticals Inc. announced that board member Leonard Sank notified the company of his intention to resign from its board of directors, effective January 1, 2026, after serving 18 years with the company. The company stated that Sank’s departure was not due to any disagreement related to operations, policies or practices, signaling an orderly governance transition rather than a sign of internal conflict, though the exit of such a long‑tenured director may still mark a notable change in the board’s composition and institutional knowledge for stakeholders.

The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.

**Spark’s Take on ORMP Stock**

According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.

The score is mainly supported by a strong, low-debt balance sheet and improving technical trend signals. Offsetting this are weak underlying operations and continued cash burn, which limit how much weight can be placed on the low P/E. Corporate actions (buyback) are a modest positive, but the JV termination adds execution risk.

To see Spark’s full report on ORMP stock, click here.

**More about Oramed Pharm**

Oramed Pharmaceuticals Inc. operates in the biopharmaceutical industry, focusing on the development of innovative oral drug delivery solutions, including oral formulations of injectable therapies, with a primary emphasis on metabolic and endocrine disorders.

**Average Trading Volume:** 178,574

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $115.8M

## Related News & Research

- [AimwellBio Reports Strong Early Demand From Hospital Systems and Researchers as FHIN Founding Cohort Takes Shape | AIMN Stock News](https://longbridge.com/en/news/285072004.md)
- [SPARC AI Hires Senergy Communication Capital | SPAIF Stock News](https://longbridge.com/en/news/285163916.md)
- [18:03 ETZibu AI Aims to Transform Patient Communication with AI-Powered Voice Agent](https://longbridge.com/en/news/285129130.md)
- [TGI's Axina Group Launches AX-Healthcare, Harnessing Sovereign-Grade AI to Transform Patient Outcomes and Global Care Delivery | TSPG Stock News](https://longbridge.com/en/news/285253005.md)
- [Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer](https://longbridge.com/en/news/285387210.md)